New ishlt guidelines support use of caredx's heartcare solutions, allomap and allosure, in routine monitoring of heart transplant patients

Brisbane, calif.--( business wire )--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the international society for heart and lung transplantation (ishlt) supporting the use of caredx's non-invasive molecular surveillance portfolio.
CDNA Ratings Summary
CDNA Quant Ranking